| __timestamp | Ligand Pharmaceuticals Incorporated | Novavax, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 19928000 |
| Thursday, January 1, 2015 | 24378000 | 30842000 |
| Friday, January 1, 2016 | 26621000 | 46527000 |
| Sunday, January 1, 2017 | 28653000 | 34451000 |
| Monday, January 1, 2018 | 37734000 | 34409000 |
| Tuesday, January 1, 2019 | 41884000 | 34417000 |
| Wednesday, January 1, 2020 | 64435000 | 145290000 |
| Friday, January 1, 2021 | 57483000 | 298358000 |
| Saturday, January 1, 2022 | 70062000 | 488691000 |
| Sunday, January 1, 2023 | 52790000 | 468946000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Ligand Pharmaceuticals Incorporated and Novavax, Inc. have shown contrasting trends in their SG&A expenses from 2014 to 2023. Ligand's expenses grew steadily, peaking in 2022 with a 210% increase from 2014. Meanwhile, Novavax experienced a dramatic surge, with expenses skyrocketing by over 2,300% during the same period, reflecting its aggressive expansion and development strategies. Notably, 2020 marked a pivotal year for Novavax, with expenses more than tripling, likely due to its COVID-19 vaccine efforts. By 2023, Novavax's SG&A expenses were nearly nine times higher than Ligand's, highlighting divergent paths in financial management. This analysis underscores the importance of strategic expense management in the biotech sector, where innovation and fiscal prudence must go hand in hand.
Comparing SG&A Expenses: GSK plc vs Ligand Pharmaceuticals Incorporated Trends and Insights
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: Exelixis, Inc. vs Novavax, Inc. Trends and Insights
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated Trends and Insights
Lantheus Holdings, Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Ultragenyx Pharmaceutical Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Mesoblast Limited
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.
Agios Pharmaceuticals, Inc. vs Novavax, Inc.: SG&A Expense Trends
MannKind Corporation and Novavax, Inc.: SG&A Spending Patterns Compared